This satellite symposium discusses current key topics in higher-risk MDS, including treatment outcome measures, latest data on new agents in clinical development, and IPSS-M scoring. At the end of the discussion portion, the experts debate featured subjects in higher-risk MDS.
This satellite symposium was sponsored by Novartis
Topics in focus:
- Overview of Higher-Risk MDS Key Topics in Focus
- Beyond a Complete Response: Achieving Durable Outcomes for Patients With HR-MDS
- Personalized Approaches to Treating HR-MDS With Novel Combinations
- Debates
- Question & Answer
Faculty:
Andrew Wei, MBBS, PhD
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Melbourne, Australia
Stef Meers, MD, PhD
AZ Klina
Antwerp, Belgium
